Chat with us
Research Assistance
Online
  • Please enter your first name.

Sweden Anti-Vascular Endothelial Growth Factor Therapeutics Market Size & Outlook

The anti-vascular endothelial growth factor therapeutics market in Sweden is expected to reach a projected revenue of US$ 126.1 million by 2030. A compound annual growth rate of -3.2% is expected of Sweden anti-vascular endothelial growth factor therapeutics market from 2025 to 2030.

  • Pharmaceuticals
    • Ophthalmology Drugs
      • Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
Revenue, 2024 (US$M)
$151.0
Forecast, 2030 (US$M)
$126.1
CAGR, 2025 - 2030
-3.2%
Report Coverage
Sweden
Sweden Anti-Vascular Endothelial Growth Factor Therapeutics Market, 2018-2030 (US$M)

This page contains premium content. Request sample data or start your free trial to explore Horizon.

  • ✔ Access to global market statistics
  • ✔ Access to company profiles
  • ✔ Free use-cases & research insights

No credit card required*

Global Market

Related Markets

Prism AI by Grand View ResearchFree to try

Ask a question about the anti-vascular endothelial growth factor therapeutics market

Every figure cited from GVR research

Sweden anti-vascular endothelial growth factor therapeutics market highlights

  • The Sweden anti-vascular endothelial growth factor therapeutics market generated a revenue of USD 151.0 million in 2024 and is expected to reach USD 126.1 million by 2030.
  • The Sweden market is expected to grow at a CAGR of -3.2% from 2025 to 2030.
  • In terms of segment, eylea was the largest revenue generating product in 2024.
  • Vabysmo is the most lucrative product segment registering the fastest growth during the forecast period.


Anti-vascular endothelial growth factor therapeutics market data book summary

Market revenue in 2024USD 151.0 million
Market revenue in 2030USD 126.1 million
Growth rate-3.2% (CAGR from 2025 to 2030)
Largest segmentEylea
Fastest growing segmentVabysmo
Historical data2018 - 2023
Base year2024
Forecast period2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationEylea, Lucentis, Beovu, Vabysmo
Key market players worldwideRoche Holding AG ADR, Biogen Inc, Pfizer Inc, Amgen Inc, Bausch Health Companies Inc, Viatris Inc, Coherus BioSciences Inc


Other key industry trends

  • In terms of revenue, Sweden accounted for 1.0% of the global anti-vascular endothelial growth factor therapeutics market in 2024.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Europe, Germany anti-vascular endothelial growth factor therapeutics market is projected to lead the regional market in terms of revenue in 2030.
  • Sweden is the fastest growing regional market in Europe and is projected to reach USD 126.1 million by 2030.

In a nationwide study conducted in Sweden, diabetic retinopathy (DR) at the time of type 2 diabetes (T2D) diagnosis was evaluated as an indicator of late-detected T2D. The findings revealed that nearly 20% of patients presented with DR upon diagnosis.

The prevalence of DR was notably higher among men, individuals of Asian descent, and those with prior histories of stroke or kidney disease. Additionally, factors such as elevated systolic blood pressure (SBP) and high HbA1c levels were found to be linked to the presence of DR. Interestingly, patients with normal weight showed a higher incidence of DR at the time of T2D diagnosis compared to those who were overweight or obese.

Conversely, a lower occurrence of DR was noted in individuals with a history of coronary heart disease (CHD). The findings of this Swedish study on diabetic retinopathy (DR) at the time of type 2 diabetes (T2D) diagnosis could have a significant impact on the anti-vascular endothelial growth factor (anti-VEGF) therapeutics market.

No credit card required*

Publish Date: Dec 17, 2024

Customize the Report

20% free customization

Include
Countries, segments, points
Tailor
To your product definition
Extend
Deeper competitor detail
Or
A fully bespoke study

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Anti-Vascular Endothelial Growth Factor Therapeutics Market Companies

NameProfile# EmployeesHQWebsite
Amgen IncView profile 26,700One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799www.amgen.com
Roche Holding AG ADRView profile 103,605Grenzacherstrasse 124, Basel, Switzerland, 4070www.roche.com
Pfizer IncView profile 88,00066 Hudson Boulevard East, New York, NY, United States, 10001-2192www.pfizer.com
Biogen IncView profile 7,570225 Binney Street, Cambridge, MA, United States, 02142www.biogen.com
Viatris IncView profile 38,0001000 Mylan Boulevard, Canonsburg, PA, United States, 15317www.viatris.com
Bausch Health Companies IncView profile 20,2702150 Saint Elzear Boulvard West, Laval, QC, Canada, H7L 4A8www.bauschhealth.com
Coherus BioSciences IncView profile 306333 Twin Dolphin Drive, Suite 600, Redwood City, CA, United States, 94065www.coherus.com

Sweden Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook will help companies and investors design strategic landscapes.


Eylea was the largest segment with a revenue share of 57.62% in 2024.

Horizon Databook has segmented the Sweden anti-vascular endothelial growth factor therapeutics market based on eylea, lucentis, beovu, vabysmo covering the revenue growth of each sub-segment from 2018 to 2030.




In a nationwide study conducted in Sweden, diabetic retinopathy (DR) at the time of type 2 diabetes (T2D) diagnosis was evaluated as an indicator of late-detected T2D. The findings revealed that nearly 20% of patients presented with DR upon diagnosis.

The prevalence of DR was notably higher among men, individuals of Asian descent, and those with prior histories of stroke or kidney disease. Additionally, factors such as elevated systolic blood pressure (SBP) and high HbA1c levels were found to be linked to the presence of DR. Interestingly, patients with normal weight showed a higher incidence of DR at the time of T2D diagnosis compared to those who were overweight or obese.

Conversely, a lower occurrence of DR was noted in individuals with a history of coronary heart disease (CHD). The findings of this Swedish study on diabetic retinopathy (DR) at the time of type 2 diabetes (T2D) diagnosis could have a significant impact on the anti-vascular endothelial growth factor (anti-VEGF) therapeutics market.

  • Sweden Anti-Vascular Endothelial Growth Factor Therapeutics Market Product Outlook (Revenue, USD Million , 2018-2030)
    • Eylea
    • Lucentis
    • Beovu
    • Vabysmo
    • Others
  • Sweden Anti-Vascular Endothelial Growth Factor Therapeutics Market Disease Outlook (Revenue, USD Million , 2018-2030)
    • Macular Edema
    • Diabetic Retinopathy
    • Retinal Vein Occlusion
    • Age-related Macular Degeneration
    • Myopic Choroidal Neovascularization

Reasons to subscribe to Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook databook

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook databook

  • Our clientele includes a mix of Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Sweden Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Sweden Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Sweden Anti-Vascular Endothelial Growth Factor Therapeutics Market, 2018-2030 (US$M)

No Access Stack Chart

Sweden Product - Anti-vascular Endothelial Growth Factor Therapeutics Market Statistics, 2024 - 2030 (US$M)

No Access Pie Chart

Sweden Product - Anti-vascular Endothelial Growth Factor Therapeutics Market Statistics, 2024 - 2030 (USD Million)

No Access

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more